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ABSTRACT We studied the effect of 17f8-estradiol (E) on
the proliferation and alkaline phosphatase activity of cultured
UMR106 cells, a clonal osteoblastic cell line. Growth rates were
reduced and alkaline phosphatase activity was increased in cells
incubated for 2 days in medium containing E (10-8 M). In
contrast, E had no effect on the growth rates or alkaline
phosphatase of a human fibroblastic cell line, S90E. The effect
of E was not observed with low cell density or at confluence.
1,25-Dihydroxyvitamin D3 antagonized the response to E.
Preincubation of the cells with dexamethasone, a potent in-
ducer of differentiation, reversed the effect of E or 1,25-
dihydroxyvitamin D3. These results indicate that cellular
and/or extracellular factors such as cell density, the phase of
the cell cycle, the state of differentiation, and the presence or
absence of other steroids influenced the response of UMR106
cells to E. Serum was removed from the culture medium to
minimize the effect of the steroids, growth factors, and nutri-
ents present in serum. A striking stimulation of alkaline
phosphatase by E occurred with serum-free conditions. This
stimulation was biphasic over an E concentration from 101-2 to
10-8 M, with the peak response at 10-1' M. The action of E on
UMR106 cells was metabolite-specific, since the isomer 17a-
estradiol produced no effect on proliferation rates or alkaline
phosphatase activity. The cyclic AMP response to parathyroid
hormone (residues 1-34) was not altered by E treatment of
these cells. In contrast, dexamethasone exposure did increase
the cyclicAMP response to parathyroid hormone. These results
demonstrate a direct effect of E on an osteoblastic cell line.
They also raise the possibility that similar or identical actions
of E occur in cultured normal osteoblasts.
Estrogens influence the skeleton, as evidenced by the loss of
bone density in postmenopausal women (1, 2) and the
preventative action of exogenous estrogens on the loss of
bone density in ovariectomized subjects (3). Estrogen ad-
ministration also produces changes related to bone and
mineral metabolism, such as increased intestinal absorption
of calcium (4) and alterations in the circulating calciotropic
hormones (4, 5). The mechanism of estrogens' action on the
skeleton is still unknown. Most investigators have postulated
an indirect pathway because of the apparent absence of
estrogen receptors in bone (6-9). We report the results of
experiments showing an effect of 17p-estradiol (E) on the
UMR106 cell line, a well-characterized osteoblastic cell
model (10-12).
MATERIALS AND METHODS
Materials. The culture media and additives were obtained
from the Tissue Culture Facility of the Lineberger Cancer
Research Center, University of North Carolina. The addi-
tives included fetal bovine serum, penicillin, streptomycin,
insulin, transferrin, selenium, and trypsin, the latter for
release of adherent cells. E and 17a-estradiol (17a-E) and
dexamethasone were purchased from Sigma. Parathyroid
hormone, as the synthetic fragment consisting of amino acid
residues 1-34 of the rat hormone [PTH-(1-34)], was obtained
from Peninsula Laboratories (San Carlos, CA). Chemicals for
the alkaline phosphatase (ALP) assay and the scintillation
fluid, Scintiverse E, were purchased from Fisher. Tritium-
labeled adenine was purchased from ICN (catalog no. 27001).
Tissue culture plates were obtained from Becton Dickinson.
Cell Culture. The UMR106 cells, a clonal line derived from
a rat osteosarcoma, were donated by T. J. Martin (University
of Melbourne, Melbourne, Australia). These cells were
maintained in continuous culture by weekly passage in
Dulbecco's modified Eagle's medium (DMEM) and Ham's
F12 medium in 1:1 proportions (vol/vol). Fetal bovine serum
(5%, vol/vol), penicillin (0.1 unit/ml) and streptomycin (100
pug/ml) were added to the medium. Under these conditions
the cells approximately double in number every 24 hr and
adhere to the plastic surface.
Cells were released from the culture plates by treatment
with 0.25% trypsin followed by suspension of the released
cells in serum-containing medium. After centrifugation (1000
x g for 5 min) the cells were washed twice with Hanks'
balanced salt solution and resuspended in DMEM/F12 me-
dium with or without fetal bovine serum as noted. Cells were
pipetted into the wells of the culture plates (Falcon multiwell
plate, catalog no. 93030, Becton Dickinson) and incubated at
37°C in 5% CO2 and humidified air. When serum-free medium
was used, insulin (6.25 ,tg/ml), transferrin (6.25 ,ug/ml), and
sodium selenate (6.25 ng/ml) were added in addition to the
antibiotics. Surface adherence and trypan blue exclusion
were not altered by incubation in serum-free medium for up
to 3 days.
A second osteoblastic cell line, ROS 17/2.8, was available
in the laboratory of T. C. Peng (Department of Pharmacol-
ogy, University of North Carolina School of Medicine).
These cells were included in the experiments involving
PTH-(1-34) and cAMP because this cell line manifested an
enhanced cAMP response to parathyroid hormone when
incubated with dexamethasone (13). The S90E cell line, a
human fibroblast line, was generously donated by D. Clem-
mons (Department of Medicine, University ofNorth Carolina
School of Medicine). The ROS 17/2.8 cells and S90E cells
were maintained in DMEM with 5% fetal bovine serum,
penicillin, and streptomycin.
Cell Counting. The cell number was determined by a
method previously reported from this laboratory (14). Brief-
Abbreviations: E, 17f8-estradiol; 17a-E, 17a-estradiol; ALP, alkaline
phosphatase; PTH-(1-34), amino acid residues 1-34 of rat parathy-
roid hormone; 1,25-D3, 1,25-dihydroxyvitamin D3.
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ly, it involves aspiration of the medium and addition of a
detergent solution to lyse plasma membranes and release
nuclei of the adherent cells. The nuclei are counted by a
Coulter Counter. These determinations were done in dupli-
cate for each well.
ALP. An established chemical assay (15) was modified so
that the enzymatic activity could be measured directly in the
wells of the tissue culture plates. The modifications included
reduction in the volume of the reagents and use of the outer
row of wells for the standard curve. The outer row was
cell-free and contained only medium. After the medium was
aspirated from each well, diethanolamine (50 mM, pH 10.5,
100 ,ul) was added. p-Nitrophenyl phosphate (2.5 mM, 50 ,ul)
was added to the wells containing cells. Wells that were free
of cells received p-nitrophenol (1 mM) in stepwise quantities
from 0 to 50 ,l. Deionized water was added to the wells
containing p-nitrophenol so that the final volume was 150 ,ul.
The tissue culture plate was incubated for 30 min at 37°C.
Then NaOH (0.1 M, 50 ,l) was added to each well.
Absorbance of p-nitrophenol in the cell-free wells or
formed by the conversion of p-nitrophenyl phosphate was
determined at 405 nm in an enzyme immunoassay plate
reader (Bio-Tek, Burlington, VT). The standard curve was
constructed from the absorbance values plotted versus the
nmol ofp-nitrophenol per well. The correlation coefficient for
absorbance versus amount of p-nitrophenol (0-50 nmol) in
every experiment was greater than 0.99. The enzymatic
activity, expressed as nmol of p-nitrophenol formed per 30
min, was determined by observing the absorbance value for
a given sample and deriving the amount ofp-nitrophenol from
the standard curve. Activities are expressed as nmol of
p-nitrophenol produced per 104 cells during the 30-min
incubation.
Experiments depicted in Tables 4 and 5 included a further
modification of the ALP assay so that the enzymatic activity
could be measured in a well in which the cell number was
determined. In the previous experiments duplicate sets of
wells were set up for cell number and ALP assay. The further
modification involved aspiration of the medium, addition of
500 ,u of Hematoll/Zaptoglobin solution (Curtin-Matheson,
Houston) to lyse cell membranes, mixing the solution in each
well, and removal of two aliquots (50 ,l each), one each for
cell counting and ALP assay. The procedures as described
above were performed for each aliquot.
cAMP Assay. cAMP production was assayed by a modifi-
cation of a published method (16). Adherent cells were
washed with DMEM and Hepes (25 nM, pH 7.4) after
removal of medium. [3H]Adenine (1 ,uCi in 0.5 ml ofDMEM
and Hepes; 1 Ci = 37 GBq) was added and the cells were
incubated for 2 hr. The radioactive medium was removed and
the cells were washed again with DMEM/Hepes. Isobutyl-
methylxanthine (0.2 mM) in DMEM/Hepes (0.45 ml) was
added. Fifteen minutes later PTH-(1-34) dissolved in
DMEM/Hepes containing 2% serum from parathyroid-
ectomized rats was added. Addition of trichloroacetic acid (1
ml, 10%) stopped the reaction.
Table 1. Effect of E on proliferation and ALP activity of
UMR106 and S90E cells
Cell no. ALP activity,
Cells Addition x 10-4 nmol/104 cells
UMR106 Vehicle 5.30 ± 0.23 27.9 ± 1.3
E, 10-10 M 5.04 ± 0.24 25.6 ± 2.0
E, 10-8 M 4.54 ± 0.20* 43.1 ± 1.5*
E, 10-6 M 4.11 ± 0.21* 36.7 ± 1.9*
S90E Vehicle 6.66 ± 0.10 11.3 ± 0.90
E, 10-10 M 6.72 ± 0.17 10.4 ± 0.62
E, 10-8 M 6.07 ± 0.20 9.2 + 1.02
E, 10-6 M 6.76 ± 0.15 8.7 ± 0.84
The values are expressed as means ± SEM of triplicate determi-
nations after a 2-day incubation. Vehicle was 95% ethanol (10 ILI).
*P < 0.05 versus control (vehicle) value.
The media were aspirated and centrifuged (1000 x g for 10
min) to sediment particles. ATP and cAMP were separated
by Dowex chromatography followed by alumina chromatog-
raphy (16). After scintillation counting of the samples, the
percent of the [3H]ATP pool converted to [3H]cAMP was
calculated as {cpm [3H]cAMP/(cpm [3H]cAMP + cpm [3H]-
ATP)} x 100.
Data Analysis. The results were analyzed by an analysis of
variance, Fisher's least differences, and Scheffe's estimate of
probability, using a TRS-80-II minicomputer and a statistical
program.
RESULTS
Table 1 documents the effect of E on the proliferation and
ALP activity ofUMR106 and S9OE cells incubated for 2 days
in medium containing fetal bovine serum (5%, vol/vol) and E
or vehicle. Compared to the effects produced by the vehicle
alone, a statistically significant reduction in the proliferation
of UMR106 cells and a concomitant increase in ALP of these
cells occurred with E concentrations of 10-8 and 10-6 M. In
contrast to this effect of E on UMR106 cells, no significant
change in either proliferation or ALP occurred in the S90E
cells.
Table 2 shows the effect of E (10-8 M), 1,25-dihydroxyvi-
tamin D3 (1,25-D3) (10-9 M), or a combination on the
proliferation and ALP of the UMR106 cells after incubation
for 1, 2, and 4 days in medium containing fetal bovine serum
(5%) and the test substances or the vehicle. From day 1 to day
2 of the incubations, the cell number in the untreated group
doubled, indicating a phase of rapid proliferation. Thereafter
the cell number increased 50% from day 2 to day 4, and
confluence of the monolayer occurred on day 4. The ALP
activity of the untreated cells increased slightly during the
phase of rapid proliferation, from a mean of 33.7 nmol after
1 day of incubation to a mean of 37.2 nmol after 2 days (Table
2). After 4 days the mean ALP value was 58.8 nmol, a 58%
increment over the activity after 2 days.
Treatment with E (10-8 M) produced a statistically signif-
icant reduction in cell number and increase in ALP after 2
Table 2. Effect of E, 1,25-D3, or a combination of the two on proliferation and ALP activity of UMR106 cells
ALP activity,
Cell no. x 10-4 nmol/104 cells
Addition Day 1 Day 2 Day 4 Day 1 Day 2 Day 4
Vehicle 6.56 + 1.11 11.9 ± 0.58 18.9 ± 0.70 33.7 ± 1.4 37.2 ± 2.2 58.8 ± 1.8
E, 10-8 M 6.48 ± 0.34 9.88 + 0.12* 18.9 ± 0.98 38.6 ± 2.5 50 ± 3.1* 60.8 ± 4.1
1,25-D3, 10-9 M 6.54 ± 0.11 12.7 ± 0.61 17.2 ± 0.82 36.9 ± 1.8 36.6 ± 3.2 52.7 ± 2.1
1,25-D3 + E 6.44 ± 0.25 11.9 ± 0.33 16.5 + 0.37 37.0 + 2.0 34.7 + 1.7 53.1 ± 0.8
Cells were cultured 1, 2, or 4 days in medium containing 5% fetal bovine serum, antibiotics, and the test substances or
vehicle. The values represent the mean ± SEM of triplicate determinations.
*P < 0.05 versus control value on the same day.
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Table 3. Effects of E, 1,25-D3, or a combination on proliferation
and ALP activity of UMR106 cells preincubated in the presence
of dexamethasone
Dexa- Cell no. ALP activity,
methasone Addition x 10-4 nmol/104 cells
- Vehicle 4.95 ± 0.19 32.8 ± 2.2
- E, 10-8 M 3.94 ± 0.40* 40.1 ± 2.1*
- 1,25-D3, 10-8 M 4.19 ± 0.21* 34.4 ± 2.3
- E + 1,25-D3 4.86 ± 0.23 30.6 ± 1.6
+ Vehicle 3.72 ± 0.54t 57.0 ± 1.4t
+ E, 10-8 M 4.26 ± 0.26* 49.0 ± 1.3*
+ 1,25-D3, 10-8 M 5.08 ± 0.22* 37.4 ± 1.5*
+ E + 1,25-D3 5.55 ± 0.30* 33.5 ± 0.9*
Cells were incubated for 24 hr in medium containing vehicle or 10-'
M dexamethasone. The medium was removed after this incubation
period and the cells were washed twice with serum-free medium.
Fresh medium containing fetal bovine serum (5%, vol/vol) was then
added and the 2-day incubation was begun. The values are expressed
as means ± SEM of triplicate determinations after the 2-day
incubation.
*P < 0.05 versus control values.
tp < 0.05 versus control values for cells not treated with dexa-
methasone.
days of incubation. These effects were not observed after 1
and 4 days of incubation. The presence of 1,25-D3 (10-9 M)
in the medium did not alter the cellular growth or ALP, a
finding consistent with our prior experience using this con-
centration of 1,25-D3 and these conditions.t The addition of
1,25-D3 in combination with E blocked the fall in cell number
and the rise in ALP associated with exposure to E alone. This
inhibition of the E effect after 2 days of incubation suggested
an antagonism between these two steroids on the UMR106
cells.
Dexamethasone is a potent inducer of differentiation in
osteoblast-enriched bone cell preparations (17) and osteo-
blastic cell lines (18, 19). We next tested the hypothesis that
UMR106 cells induced to differentiate by exposure to dexa-
methasone might be more or less responsive to E. The results
of this experiment are depicted in Table 3. When the cells
were not exposed to dexamethasone for 24 hr prior to the
treatment with E, 1,25-D3, or a combination, the results
shown in Table 3 were similar to those shown in Table 2 even
though a 10-8 M concentration of 1,25-D3 was chosen in this
experiment. As anticipated, E reduced the cell number and
increased ALP after a 2-day incubation. 1,25-D3 also reduced
cell number but did not significantly increase ALP of the
cells. The combination of the two steroids produced results
indistinguishable from those of controls without steroids,
confirming the previous experiments (Table 2) and demon-
strating again the antagonistic interaction of E and 1,25-D3.
The preincubation with dexamethasone followed by a
2-day incubation with vehicle alone produced a significant fall
in cell number and a striking increase in ALP (Table 3). The
treatment with E during the 2-day incubation following
differentiation by dexamethasone produced a reversal of the
previously observed E actions. Cells pretreated with dexa-
methasone and then exposed to E increased in number and
contained less ALP after 2 days of incubation. A similar
response was produced by the sequential exposure to dexa-
methasone and 1,25-D3 (Table 3). However, the combination
of E and 1,25-D3, both at 10-8 M, after dexamethasone
priming increased proliferation further and reduced the ALP
to the level associated with the untreated cells incubated with
vehicle alone during the entire incubation. These unexpected
Table 4. Effect of E on proliferation and ALP activity of
UMR106 cells incubated for 3 days in serum-free medium
Cell no. ALP activity,
Addition x 10-4 nmol/104 cells
Vehicle 9.65 ± 0.75 23.6 ± 0.86
E, 10-12 M 8.40 ± 0.30 29.6 ± 0.68
E, 10-11M 9.25 ± 0.30 21.8 ± 0.42
E, 10-10 M 5.30 ± 0.40t 49.6 ± 2.Ot
E, 10-9 M 7.30 ± 0.40* 31.6 ± 0.4*
E, 10-8 M 7.80 ± 0.25* 29.8 ± 1.8*
Cell counts and ALP activities were determined in aliquots of cell
lysates from the same well. The values are expressed as means ±
SEM.
*P < 0.025 versus control value.
tP < 0.01 versus control value.
responses of the dexamethasone-primed cells to E, 1,25-D3,
or the combination indicated that the state of differentiation
and perhaps the inducing agent influenced the response to E
of the UMR106 cells.
To minimize the effects of steroids present in the fetal
bovine serum, experiments were performed using culture
medium supplemented with insulin, transferrin, and selenium
but no serum. In these experiments cells were incubated in
serum-free medium for 1 day prior to the commencement of
the experiment in an attempt to lower the intracellular
content of estrogens derived from the prior exposure to
serum during the plating procedure and the previous contin-
uous culture in serum-containing medium. After this day the
medium was removed and replaced by fresh serum-free
medium. The incubation period was also extended to 3 days
because of the anticipated reduction in the rate of cell
proliferation during culture in serum-free medium.
Incubation of UMR106 cells in serum-free medium con-
taining E over a range of concentrations (10-12 to 10-8 M) led
to changes in the proliferation rates and ALP activities (Table
4). E concentrations from 10-10 to 10-8 M were associated
with statistically significant reductions in cell number relative
to the group exposed to vehicle. Likewise, statistically
significant increases in ALP were associated with these same
concentrations of E. Interestingly, the peak ALP activity was
associated with 10-10 M rather than the highest E concen-
tration tested, 10-8 M.
Table 5 compares the effect of E and its isomer 17a-E on
the proliferation and ALP activity of these cells under
serum-free conditions. No statistically significant changes in
cell number or ALP were observed after the 3-day incubation
in the presence of 17a-E. In contrast, E reduced cell number
and increased ALP activity at the three concentrations
tested, 10-11 to 10' M. The reduction in cell number was
nearly uniform for the three doses. Once again the peak ALP
Table 5. Effects of 17a-E and E on proliferation and ALP
activity of UMR106 cells incubated for 3 days in
serum-free medium
Cell no. ALP activity,
Addition x 10-4 nmol/104 cells
Vehicle 7.10 ± 0.35 19.6 ± 3.8
17a-E, 10-11 M 8.55 ± 0.55 17.2 ± 2.8
17a-E, 10-10 M 7.10 ± 0.20 23.6 ± 4.4
17a-E, 10' M 6.80 ± 0.25 23.2 ± 9.8
Vehicle 7.20 ± 0.70 19.4 ± 2.0
E, 10-11 M 3.95 ± 0.35* 52.2 ± 3.0*
E, 10-10 M 3.50 ± 0.20* 56.2 ± 2.4*
E, 10-9 M 3.90 ± 0.40* 35.6 ± 3.6*
Cell counts and ALP activities were determined in aliquots of cell
lysates from the same well. The values are means ± SEM.
*P < 0.01 versus control value.
tGray, T. K., Shapiro, R., D'Amico, C. N. & Dodd, R. C., Ab-
stracts of the American Society for Bone and Mineral Research,
June 15-18, 1985, Washington, DC, A58.
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FIG. 1. Basal and PTH-(1-34)-induced cAMP in UMR106 or ROS
17/2.8 cells. DEX, dexamethasone.
response was associated with the 10-10 M concentration. In
contrast to the results in Table 4, a significant increase in ALP
was associated with the 10-11 M concentration of E in this
experiment.
Basal cAMP concentration and the PTH-1(1-34)-induced
rise in cAMP were studied in UMR106 cells and in a second
osteoblastic cell line, ROS 17/2.8. Both cell lines were
incubated for 2 days with E (10-' M), dexamethasone (10-6
M), or the vehicle and then assayed for cAMP before and
after acute PTH-(1-34) challenge. Fig. 1 depicts the percent
conversion of radiolabeled ATP to radiolabeled cAMP in the
basal state and after stimulation by PTH-(1-34) at one of three
doses. The basal cAMP levels in the ROS 17/2.8 cells were
slightly higher than those in the UMR106 cells. The cAMP
response to PTH-(1-34) in the cells incubated With vehicle
was nearly identical (Fig. 1). Incubation with E did not
change the basal cAMP levels or the response to PTH-(1-34)
in either cell line. However, dexamethasone treatment of the
ROS 17/2.8 cells markedly increased the cAMP response to
PTH-(1-34). In contrast, UMR106 cells exposed to dexa-
methasone manifested little or no change in the cAMP
response to PTH-(1-34) relative to the E or vehicle groups.
DISCUSSION
The mechanism of action of E on bone is uncertain despite
studies over the past three decades reporting effects on bone
in rodents and quail and on mineral metabolism in humans
(1-5, 20-28). The studies in rodents and quail have found
effects of exogenous estrogens on osteoblasts, their precur-
sors, or both (20-28). Endosteal proliferation and meta-
physeal sclerosis were observed in several studies, implying
an anatomic localization of the estrogen effect. A stimulatory
action of estradiol and progesterone on bone formation was
observed in an established model of matrix-indiuced osteo-
induction (29). Nevertheless these studies could not distin-
guish the direct or indirect effects of estradiol on the
osteoblasts.
Several attempts to find E receptors in bone were not
successful (6-9). Despite this lack of success, we reexamined
the possibility that E might act directly on osteoblasts by
studying its effect on UMR106 cells, a clonal line derived
from a rat osteosarcoma (10). This cell line expresses many
phenotypic characteristics of normal osteoblasts (10-12), and
in these experiments we utilized UMR106 cells as surrogate
osteoblasts. Our results show that E acted directly, stimu-
lating the ALP activity (corrected for the cell number) in a
dose-dependent manner. The ALP was corrected for the cell
number at the end of each incubation period as emphasized
by Chen and her associates (17) to avoid misinterpretations
of altered enzyme activity due to changes in cell number
rather than enzyme content per cell. We have expressed the
enzyme activity as nanomoles of substrate hydrolyzed per 30
min per 104 cells, and we have designated this corrected
measurement as the ALP activity. Generally the ALP activity
of UMR106 cells and osteoblasts has been used as a gauge of
differentiation, with higher enzyme activity indicating en-
hanced cell differentiation (17-19). In view of this fact, E
apparently induced the differentiation of UMR106 cells
specifically. The response is specific for both cell type and
metabolite because the fibroblasts did not respond in the
manner of the UMR106 cells and the isomer 17a-E was
inactive when tested at 10-11 to 10-9 M under serum-free
conditions. E treatment did not alter the responsiveness of
the UMR106 cells or the ROS 17/2.8 cells to PTH-(1-34),
while dexamethasone augmented this response in both,
although to a larger degree in the ROS 17/2.8 cells than in the
UMR106 cells.
Our results suggest that the direct action of E on the
UMR106 cells depends on a complex set of cellular and/or
extracellular events. The ALP response to E occurred
consistently during the rapid proliferative phase of UMR106
culture but not during the first day, when cell density was
low, or on the fourth day, when the cells were confluent. This
temporal pattern suggests that cell density and the cell cycle
influence responsiveness to E. This type of response is not
unique to E, since it has already been described in osteoblasts
for 1,25-D3 (18, 28). Exposure of rapidly proliferating ROS
17/2.8 cells, another osteoblastic cell line, to 1,25-D3 in-
creased the ALP activity, but this response was not present
in confluent cells (18). Likewise 1,25-D3 increased the ALP
activity of proliferating MC3T-E1 cells, a murine osteoblastic
cell line, but not when these cells were confluent (28). The
responsiveness of the MC3T3 cells correlated with the
expression of 1,25-D3 receptors in these cells (28). Variation
in the expression of 1,25-D3 receptors in osteoblasts during
the cell cycle has been reported (30). The nature of the
UMR106 response to E is very similar to the responses of
osteoblastic cells or cell lines to 1,25-D3. Given this similar-
ity, it is possible that E receptors, if present in the UMR106
cells, vary their expression during the phases of proliferation
and confluence and thereby determine to a large extent the
cellular response.
The interactions between E, 1,25-D3, and dexamethasone
observed in these experiments are both interesting and
puzzling. The antagonism between E and 1,25-D3 seems
clear, and it suggests that the UMR106 cells exposed to both
substances are not capable of manifesting the changes due to
E alone, presumably because the cellular responses to each
affect or inhibit the response to the other. The more inter-
esting and puzzling result is the fact that UMR106 cells
induced to differentiate by exposure to dexamethasone
manifested a response to E opposite that seen in cells not
treated with dexamethasone. This observation indicates that
the state of differentiation and possibly the inducing agent
determine the response to E. Given the temporal pattern of
the E response and the dexamethasone experiments, we
suggest that the UMR106 response to E depends on multiple
factors, including cell density, proliferation rate or phase of
the cell cycle, the state of differentiation, and the presence or
absence ofgrowth factors and other steroids. We hypothesize
that synchronization of these factors might produce a max-
imal response to E and that loss of synchrony might reduce
the magnitude of the response or, under certain circum-
stances, lead to a reversal of the E effect.
The removal of serum from the culture medium allowed us
to observe the effect ofE on the UMR106 cells in the absence
of the growth factors, steroids, and nutrients derived from
serum. Under these conditions a stimulation ofALP activity,
the marker of differentiation, was clearly seen when E
concentrations from 10-12 to 10-8 M were present in the
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medium. The ALP response to E appeared to be biphasic
under serum-free conditions, reaching its peak at 10-10 M
(Tables 4 and 5).
Removal of serum also influenced the E-dependent inhi-
bition of UMR106 proliferation observed in earlier experi-
ments that employed culture medium containing fetal bovine
serum. The suppression of cell growth by E under serum-free
conditions was not dose dependent. It seems unlikely that
this is a nonspecific or toxic action of E, since its isomer,
17a-E, produced no significant change in cell proliferation
when tested over the same dose range.
The, lack of a dose response in the suppressed cellular
growth versus the biphasic pattern of ALP stimulation
suggests to us that the molecular mechanisms underlying
these two processes are different and distinct. The apparent
dose-dependent inhibition of proliferation observed when
serum was present in the culture medium is another example
of the complex interactions between extracellular factors that
modulate the E response.
The demonstration of a direct action of E on the UMR106
cells raises several important questions. Do these cells
contain E receptors? We assume that they do and we
anticipate variation in receptor expression during the cell
cycle analogous to the 1,25-D3 receptors. Does E act directly
on normal osteoblasts? Do normal osteoblasts contain E
receptors? The results presented here should stimulate in-
vestigators in the area of bone cell biology to address these
questions.
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